OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Sahai on the Role of Genomic Profiling in Pancreatic Cancer

June 7th 2019

Vaibhav Sahai, MBBS, assistant professor of medicine at the University of Michigan, discusses the role of genomic profiling in pancreatic cancer.

Dr. Ferguson Discusses AEs Associated With Surgery in Cervical Cancer

June 6th 2019

Sarah Ferguson, MD, FRCSC, associate professor of gynecologic oncology, University of Toronto, Princess Margaret Cancer Centre, discusses adverse events associated with surgery in cervical cancer.

Dr. Kopetz on the Correlation Between Tumor Sidedness and Biomarkers in CRC

June 6th 2019

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the correlation between tumor sidedness and biomarkers in colorectal cancer.

Dr. McKinney Discusses Ongoing Work in MCL

June 6th 2019

Matthew S. McKinney, MD, assistant professor of medicine, Duke University School of Medicine, co-director of the Molecular Tumor Board, Duke Cancer Institute, discusses ongoing work in mantle cell lymphoma.

Dr. McDermott on the Promise of Pembrolizumab in Non-Clear Cell RCC

June 6th 2019

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the promise of single-agent pembrolizumab in advanced non–clear cell renal cell carcinoma.

Dr. Yu on the Drawbacks of Radiation Therapy in Prostate Cancer

June 6th 2019

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses drawbacks of radiation therapy in prostate cancer.

Dr. Bauml on the Use of Immunotherapy in Oligometastatic NSCLC

June 6th 2019

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the use of immunotherapy in oligometastatic non–small cell lung cancer.

Dr. Messersmith on Molecular Markers to be Aware of in CRC

June 5th 2019

Wells A. Messersmith, MD, co-director of the Developmental Therapeutics Program, and director, GI Cancer Program, at the University of Colorado School of Medicine, discusses molecular markers to be aware of in patients with colorectal cancer (CRC).

Dr. Gasparetto on Therapies for Patients With Penta-Refractory Myeloma

June 5th 2019

Cristina Gasparetto, MD, an associate professor of medicine and director, Multiple Myeloma Program at Duke Cancer Institute, discusses therapies for patients with penta-refractory multiple myeloma.

Dr. Sonpavde on Agents Under Investigation in PD-L1-Low Bladder Cancer

June 5th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses therapeutic agents under investigation for patients with PD-L1–low bladder cancer.

Dr. Cheng on the Role of T-DM1 in HER2+ Breast Cancer

June 5th 2019

Yee Chung Cheng, MD, associate professor of medicine, Medical College of Wisconsin, discusses the role of T-DM1 in patients with HER2-positive breast cancer.

Dr. Fenske Discusses Targets Under Evaluation in MCL

June 5th 2019

Timothy Fenske, MD, MS, an associate professor at the Medical College of Wisconsin, discusses targets under evaluation in mantle cell lymphoma.

Dr. Ready on the Benefit of PD-L1 Inhibition in SCLC

June 5th 2019

Neal E. Ready, MD, PhD, professor of medicine, Duke University School of Medicine, member, Duke Cancer Institute, discusses the benefit of PD-L1 inhibition in small cell lung cancer.

Dr. Abedin on the Role of Venetoclax Plus Obinutuzumab in CLL

June 4th 2019

Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses the role of venetoclax plus obinutuzumab in chronic lymphocytic leukemia.

Dr. Maziarz on Unanswered Questions With CAR T-Cell Therapy in DLBCL

June 4th 2019

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses unanswered questions with CAR T-cell therapy in diffuse large B-cell lymphoma.

Dr. Shuch on Caveats of Avelumab/Axitinib Combination in RCC

June 4th 2019

Brian M. Shuch, MD, director, Kidney Cancer Program, Alvin & Carrie Meinhardt Endowed Chair of Kidney Cancer Research, University of California, Los Angeles Institute of Urologic Oncology, discusses caveats of the avelumab plus axitinib combination in frontline advanced renal cell carcinoma.

Dr. Stinchcombe on the Benefit of Alectinib in ALK+ NSCLC

June 1st 2019

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the benefit of alectinib in the treatment of patients with ALK-positive non–small cell lung cancer.

Addressing Unmet Needs in Medullary Thyroid Cancer

June 1st 2019

Rozita Yarmand, PhD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders-Research, The University of Texas MD Anderson Cancer Center, discusses unmet needs in medullary thyroid cancer.

Dr. Sweetenham on Unanswered Questions With CAR T-Cell Therapy in Pediatric ALL

June 1st 2019

John Sweetenham, MD, associate director for clinical affairs, Harold G. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses unanswered questions with CAR T-cell therapy in pediatric acute lymphoblastic leukemia.

Dr. Schmid on Challenges Concerning Biosimilars in Oncology

May 31st 2019

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses challenges with biosimilars in oncology.